As we previously reported, JAMP sought leave to commence an application against Janssen under the abuse of dominance provisions of the Competition Act (the Act), relating to ustekinumab (Janssen’s ...
JAMP filed an application with the Competition Tribunal on July 26, 2024, seeking leave to bring an abuse of dominance case against Janssen relating to ustekinumab (Janssen’s STELARA). JAMP proposes ...
REYKJAVIK, Iceland and BOUCHERVILLE, Quebec, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines ...
REYKJAVIK, Iceland and BOUCHERVILLE, Quebec, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines ...
JAMP Pharma's new head office on Boucherville, Québec. (c) Bénédicte Brocard (CNW Group/Fonds de solidarité FTQ) Boucherville, Quebec – October 25, 2016 — JAMP Pharma, a Boucherville based generic ...
The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Both the ...
Add Yahoo as a preferred source to see more of our stories on Google. A monitor is seen during a heart catheterization. A prescription medication to treat congestive heart failure is being recalled in ...
More than 100 high school seniors from Baylor College of Medicine's magnet health professions' network were guests at The Texas Premedical Leadership Symposium hosted by BCM and the Joint Admission ...
PrJamtekiTM is the second biosimilar developed under this partnership that receives marketing authorization in Canada. REYKJAVIK, Iceland and BOUCHERVILLE, Quebec, Nov. 14, 2023 (GLOBE NEWSWIRE) -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results